Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVAX stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Implied fair value · at NVAX's multiple
Needs NVAX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NOVAVAX, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Illumina, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
NVAX vs MRNA
BioNTech SE
NVAX vs BNTX
Emergent BioSolutions Inc.
NVAX vs EBS
ASTRAZENECA PLC
NVAX vs AZN
GSK plc
NVAX vs GSK
THERMO FISHER SCIENTIFIC INC.
NVAX vs TMO
AGILENT TECHNOLOGIES, INC.
NVAX vs A
DANAHER CORP /DE/
NVAX vs DHR
BIO-RAD LABORATORIES, INC.
NVAX vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
NVAX vs PACB
Natera, Inc.
NVAX vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NVAX can sustain its 64.7% revenue growth while improving capital efficiency and avoiding distress, then NVAX may merit a re-rating because its current valuation multiples are far below ILMN and below the DCF range; otherwise, the discount likely reflects fundamental risk rather than clear undervaluation.
NVAX trades at a steep discount to ILMN on both earnings and sales multiples, but the gap is far larger than the operating profile alone would justify. The current price of $7.32 is also below the low end of ILMN-implied range and roughly within the lower end of its own historical band, while still far under DCF-based estimates.
Supporting Metrics
